Coal dust nanoparticles (CD-NPs) — the primary driver of pneumoconiosis — significantly reduced type II alveolar cell viability, suppressed proliferation, and triggered apoptosis in vitro. Resveratrol reversed these effects. In a mouse pneumoconiosis model, resveratrol also reduced inflammatory cell infiltration, fibrotic lesion formation, and lung function decline caused by CD-NP exposure, offering a dual protective profile across acute cellular injury and chronic structural remodeling.
Pneumoconiosis remains one of the most prevalent and irreversible occupational lung diseases globally, with no approved disease-modifying therapy. Resveratrol's known mechanisms — SIRT1 activation, NF-κB suppression, and TGF-β pathway modulation — are plausible pathways through which it could blunt both the inflammatory cascade and subsequent fibrogenesis, though this abstract does not specify which mechanisms were interrogated here, a meaningful gap. The finding that a single polyphenol addresses both acute epithelial injury and chronic fibrotic progression is mechanistically notable, not merely additive.
Limitations are substantial: this is preclinical work (cell culture plus mouse model) with no human pharmacokinetic data, no dose-response curves reported, and no comparison to existing antifibrotic agents like pirfenidone. Resveratrol's bioavailability in humans remains a persistent clinical obstacle. Regarded alongside prior resveratrol-fibrosis literature, this study is confirmatory in direction but adds occupational lung disease context. Incrementally useful; far from clinical translation.